Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists

A Winiarska, M Knysak, K Nabrdalik… - International Journal of …, 2021 - mdpi.com
The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

RZ Alicic, EJ Cox, JJ Neumiller, KR Tuttle - Nature Reviews Nephrology, 2021 - nature.com
As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

MHA Muskiet, L Tonneijck, MM Smits… - Nature Reviews …, 2017 - nature.com
The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function

J Rowlands, J Heng, P Newsholme… - Frontiers in …, 2018 - frontiersin.org
The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

Anti‐inflammatory effects of GLP‐1‐based therapies beyond glucose control

YS Lee, HS Jun - Mediators of inflammation, 2016 - Wiley Online Library
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone mainly secreted from intestinal L
cells in response to nutrient ingestion. GLP‐1 has beneficial effects for glucose homeostasis …

[HTML][HTML] The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

D Athauda, T Foltynie - Drug discovery today, 2016 - Elsevier
Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

ELABELA and an ELABELA fragment protect against AKI

H Chen, L Wang, W Wang, C Cheng… - Journal of the …, 2017 - journals.lww.com
Renal ischemia-reperfusion (I/R) injury is the most common cause of AKI, which associates
with high mortality and has no effective therapy. ELABELA (ELA) is a newly identified 32 …

Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia–reperfusion-induced kidney injury via the JAK/STAT pathway

X Zhao, E Zhang, X Ren, X Bai, D Wang, L Bai… - Biological Research, 2020 - Springer
Background Kidney ischemia–reperfusion injury is a common pathophysiological
phenomenon in the clinic. A large number of studies have found that the tyrosine protein …

Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease

GA Badawi, MA Abd El Fattah, HF Zaki… - …, 2017 - Springer
The present study investigated the possible relationship between pro-inflammatory
cytokines and programmed nigral neuronal death in rotenone model of Parkinson's disease …

Systematic understanding of pathophysiological mechanisms of oxidative stress-related conditions—diabetes mellitus, cardiovascular diseases, and ischemia …

M Wang, Y Liu, Y Liang, K Naruse… - Frontiers in …, 2021 - frontiersin.org
Reactive oxygen species (ROS) plays a role in intracellular signal transduction under
physiological conditions while also playing an essential role in diseases such as …